Inception

Within 6 months of our founding, we were thrust into the COVID-19 pandemic. Even with the global supply chains collapsing around us, we were successful in establishing manufacturing facilities for RT-PCR IVDs in both France and India. 

​

COVID-19 RT-PCR Disruption

We further used our expertise to bring about a disruption in the COVID-19 RT-PCR testing industry with the launch of the Detection Expert SARS-CoV-2 rRT-PCR assay in France and India.  In order to facilitate a greater adoption of RT-PCR testing in comparison to 'Rapid' tests, we decided to disrupt the industry by lowering the cost of our COVID-19 RT-PCR diagnostic to less than USD 2.5

​

Mobile Laboratory Innovation and Patient Testing Disruption

We proceeded further to design a BSL-2 compliant mobile RT-PCR testing laboratory for COVID-19 testing with an ambitious target of reducing the cost of patient testing to under USD 5. Our technology was supported by the Hon' Home Minister of India, Shri Amit Shah. The Indian government leveraged this opportunity to scale-up surveillance programs for COVID-19 across different states using molecular diagnostic testing as the front-line screening tool in lieu of 'RAPID' tests. The cost-savings for the Indian government due to our efforts were in the billions of dollars.

​

Repositioning Manufacturing Supply-Chains Back To Europe

In France, our organisation was able to demonstrate that IVD manufacturing in Europe could be highly competitive in comparison to manufacturing in East-Asia. Our pricing strategy was successful in capturing a large market share in France, and we demonstrated that supply-chains indeed could be transferred back to Europe while maintaining price competitiveness.